Vistagen Therapeutics Inc., of South San Francisco, said it secured exclusive worldwide commercial rights to three patent-pending stem cell technologies from University Health Network, Canada's largest research hospital. The newly licensed technologies relate to the development of stem cells into heart, liver and cartilage cells for multiple potential commercial applications, including drug rescue and regenerative therapies for heart disease, liver disease and osteoarthritis.